Polar Capital Holdings Plc Acquires 2,637,524 Shares of Taysha Gene Therapies, Inc. $TSHA

Polar Capital Holdings Plc grew its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 49.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,931,403 shares of the company’s stock after purchasing an additional 2,637,524 shares during the quarter. Polar Capital Holdings Plc owned approximately 2.90% of Taysha Gene Therapies worth $43,623,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in TSHA. Capricorn Fund Managers Ltd bought a new stake in Taysha Gene Therapies during the 4th quarter valued at about $1,650,000. GSA Capital Partners LLP grew its stake in Taysha Gene Therapies by 969.0% in the 3rd quarter. GSA Capital Partners LLP now owns 477,749 shares of the company’s stock worth $1,562,000 after acquiring an additional 433,059 shares in the last quarter. Ally Bridge Group NY LLC purchased a new position in shares of Taysha Gene Therapies during the third quarter worth approximately $6,207,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of Taysha Gene Therapies during the fourth quarter valued at approximately $1,697,000. Finally, SG Americas Securities LLC boosted its holdings in shares of Taysha Gene Therapies by 2,271.8% in the fourth quarter. SG Americas Securities LLC now owns 781,474 shares of the company’s stock valued at $4,298,000 after purchasing an additional 748,525 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TSHA has been the topic of several research analyst reports. Chardan Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Canaccord Genuity Group increased their price target on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, April 6th. Needham & Company LLC raised their price target on Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Finally, Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Taysha Gene Therapies has a consensus rating of “Buy” and an average price target of $11.64.

Taysha Gene Therapies Price Performance

NASDAQ TSHA opened at $5.85 on Wednesday. The company has a market cap of $1.68 billion, a PE ratio of -15.39 and a beta of 1.19. The firm’s 50 day moving average price is $5.83 and its 200-day moving average price is $5.20. The company has a debt-to-equity ratio of 0.23, a quick ratio of 14.04 and a current ratio of 14.04. Taysha Gene Therapies, Inc. has a 52-week low of $2.25 and a 52-week high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Sell-side analysts forecast that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total transaction of $892,000.00. Following the completion of the sale, the insider directly owned 1,136,410 shares in the company, valued at $5,068,388.60. This represents a 14.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.